United Stateshea

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the federal government. President Donald Trump, then starting his first term, was excoriating them for their high prices. A mounting number of reports showed that soaring costs were even forcing some diabetics to ration insulin. Ricks, the 11th CEO in Lilly's 150-year history, concedes that one was a public-relations nightmare. Almost a decade later, the mood at Lilly has shifted dramatically. The company's hit diabetes shot, Mounjaro, and obesity shot, Zepbound, have transformed its fortunes and, in many ways, its public image. We speak with Madison Muller, Bloomberg News Healthcare Reporter, for a closer look.

INVO Fertility (NASDAQ:IVF) recorded a 23% increase in year-over-year revenue to $2.02 million for the first quarter of 2026.

Ensign Group (NASDAQ:ENSG) issued a quarterly cash dividend of $0.0650 per common share to reward its investors.

Infinitus CEO Ankit Jain joined Bloomberg Open Interest to explain why the next generation of AI won't be copilots or chatbots but autonomous agents that handle healthcare tasks end-to-end. He discusses insurance approvals, rising AI costs, healthcare inefficiencies, and why the industry must focus on outcomes instead of computation.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk.

Prestige Consumer Healthcare (NYSE:PBH) closed its acquisition of the Breathe Right brand for $1.045 billion.

Kenyan police fired teargas at protesters demonstrating against a planned quarantine facility for US servicemen and citizens exposed to the Ebola virus. Bloomberg's Helen Nyambura reports.

GSK agreed to buy Nuvalent in a deal valued at $10.6 billion, adding a biotech firm that's developing treatments for lung cancer as the British pharmaceutical company seeks to rebuild its oncology franchise. Sam Fazeli of Bloomberg Intelligence has more.

The Ebola Bundibugyo strain is spreading fast with no known treatment or vaccine, and the international system built to contain outbreaks is in crisis. Bloomberg's Jennifer Zabasajja reports.